Similar articles

• In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.

  Aldridge KE, Henderberg A, Sanders CV. Aldridge KE, et al. J Antimicrob Chemother. 1990 Sep;26(3):353-9. doi: 10.1093/jac/26.3.353. J Antimicrob Chemother. 1990. PMID: 2228826
• Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.

  Stratton CW, Weeks LS, Aldridge KE. Stratton CW, et al. Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):321-30. doi: 10.1016/0732-8893(92)90018-o. Diagn Microbiol Infect Dis. 1992. PMID: 1611847
• Enhanced antimicrobial activity of old and new beta-lactams against cefoxitin-resistant Bacteroides fragilis group isolates by beta-lactamase inhibitors.

  Aldridge KE, Henderberg A, Sanders CV. Aldridge KE, et al. J Antimicrob Chemother. 1990 May;25(5):873-5. doi: 10.1093/jac/25.5.873-a. J Antimicrob Chemother. 1990. PMID: 2373670 No abstract available.
• Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.

  Johnson CC. Johnson CC. Clin Infect Dis. 1993 Jun;16 Suppl 4:S371-6. doi: 10.1093/clinids/16.supplement_4.s371. Clin Infect Dis. 1993. PMID: 8324150 Review.
• Newer beta-lactam agents and the Bacteroides fragilis group.

  Cuchural GJ Jr. Cuchural GJ Jr. Pharmacotherapy. 1991;11(2 ( Pt 2)):51S-55S. Pharmacotherapy. 1991. PMID: 2041832 Review.